Turning Point Therapeutics Stock Price, News & Analysis (NASDAQ:TPTX)

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Turning Point Therapeutics (NASDAQ:TPTX) issued its earnings results on Tuesday, August, 6th. The company reported ($0.70) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.65) by $0.05. View Turning Point Therapeutics' Earnings History.

Turning Point Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Turning Point Therapeutics.

9 analysts have issued twelve-month price targets for Turning Point Therapeutics' stock. Their predictions range from $42.00 to $70.00. On average, they expect Turning Point Therapeutics' stock price to reach $54.56 in the next twelve months. This suggests a possible upside of 47.8% from the stock's current price. View Analyst Price Targets for Turning Point Therapeutics.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Turning Point Therapeutics.

News stories about TPTX stock have trended somewhat positive on Sunday, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Turning Point Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Turning Point Therapeutics.

Turning Point Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 2,280,000 shares, an increase of 17.5% from the August 30th total of 1,940,000 shares. Based on an average daily volume of 224,000 shares, the short-interest ratio is presently 10.2 days. Approximately 10.6% of the shares of the stock are sold short. View Turning Point Therapeutics' Current Options Chain.

Some companies that are related to Turning Point Therapeutics include The Medicines (MDCO), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), United Therapeutics (UTHR), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Evotec (EVTCY), Allakos (ALLK), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), Emergent Biosolutions (EBS) and Alkermes (ALKS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include H&E Equipment Services (HEES), Immunomedics (IMMU), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Applied Genetic Technologies (AGTC), Aimmune Therapeutics (AIMT), Alkermes (ALKS), Allena Pharmaceuticals (ALNA), Alnylam Pharmaceuticals (ALNY) and Amyris (AMRS).

(TPTX) raised $167 million in an IPO on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Turning Point Therapeutics' lock-up period expired on Monday, October 14th. Turning Point Therapeutics had issued 9,250,000 shares in its public offering on April 17th. The total size of the offering was $166,500,000 based on an initial share price of $18.00. Since the expiration of Turning Point Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TPTX stock can currently be purchased for approximately $36.90.

Turning Point Therapeutics has a market capitalization of $1.16 billion. Turning Point Therapeutics employs 50 workers across the globe.View Additional Information About Turning Point Therapeutics.

The official website for Turning Point Therapeutics is http://www.tptherapeutics.com/.

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]